Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating…
– exoSTING resulted in localized STING pathway activation and dose-dependent immune activation – – Intratumoral administration of exoSTING was well tolerated and demonstrated tumor…